0001209191-18-009631.txt : 20180213
0001209191-18-009631.hdr.sgml : 20180213
20180213170450
ACCESSION NUMBER: 0001209191-18-009631
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180209
FILED AS OF DATE: 20180213
DATE AS OF CHANGE: 20180213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bazemore Robert B
CENTRAL INDEX KEY: 0001620152
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35945
FILM NUMBER: 18604626
MAIL ADDRESS:
STREET 1: 33 HAYDEN AVE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Epizyme, Inc.
CENTRAL INDEX KEY: 0001571498
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261349956
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 TECHNOLOGY SQUARE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-229-5872
MAIL ADDRESS:
STREET 1: 400 TECHNOLOGY SQUARE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-09
0
0001571498
Epizyme, Inc.
EPZM
0001620152
Bazemore Robert B
C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
1
0
0
President & CEO
Stock Option (Right to Buy)
16.00
2018-02-09
4
A
0
265860
0.00
A
2028-02-08
Common Stock
265860
265860
D
This option was granted on February 9, 2018 pursuant to the Company's 2013 Stock Incentive Plan with respect to 265,860 shares of Common Stock, with 25% vesting on February 9, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
/s/ Adriana Sullivan, attorney-in-fact
2018-02-13